COVID-19: Does the Infectious Inoculum Dose-response Relationship Contribute to Understanding Heterogeneity in Disease Severity and Transmission Dynamics?

Overview

Journal Med Hypotheses

Specialty General Medicine

Date 2020 Dec 8

PMID 33288314

Citations 44

Authors

Wim Van Damme

Ritwik Dahake

Remco van de Pas

Guido Vanham

Yibeltal Assefa

Affiliations

Soon will be listed here.

Abstract

The variation in the speed and intensity of SARS-CoV-2 transmission and severity of the resulting COVID-19 disease are still imperfectly understood. We postulate a dose-response relationship in COVID-19, and that "the dose of virus in the initial inoculum" is an important missing link in understanding several incompletely explained observations in COVID-19 as a factor in transmission dynamics and severity of disease. We hypothesize that: (1) Viral dose in inoculum is related to severity of disease, (2) Severity of disease is related to transmission potential, and (3) In certain contexts, chains of severe cases can build up to severe local outbreaks, and large-scale intensive epidemics. Considerable evidence from other infectious diseases substantiates this hypothesis and recent evidence from COVID-19 points in the same direction. We suggest research avenues to validate the hypothesis. If proven, our hypothesis could strengthen the scientific basis for deciding priority containment measures in various contexts in particular the importance of avoiding super-spreading events and the benefits of mass masking.

Citing Articles

Explaining Racial and Ethnic Inequities in SARS-CoV-2-Related Outcomes: Results from a Serosurvey in Chicago.

Eyo C, Schrock J, Hayford C, Ryan D, Saber R, Benbow N J Racial Ethn Health Disparities. 2025; .

PMID: 40063297 DOI: 10.1007/s40615-025-02362-4.

Barcoded SARS-CoV-2 viruses define the impact of duration and route of exposure on the transmission bottleneck in a hamster model.

Trende R, Darling T, Gan T, Wang D, Boon A Sci Adv. 2025; 11(3):eads2927.

PMID: 39813353 PMC: 11778309. DOI: 10.1126/sciadv.ads2927.

Symptom propagation in respiratory pathogens of public health concern: a review of the evidence.

Asplin P, Mancy R, Finnie T, Cumming F, Keeling M, Hill E J R Soc Interface. 2024; 21(216):20240009.

PMID: 39045688 PMC: 11267474. DOI: 10.1098/rsif.2024.0009.

Severity of respiratory tract infections depends on the infectious dose. Perspectives for the next pandemic.

Molbak K, Sorensen T, Bhatt S, Lyngse F, Simonsen L, Aaby P Front Public Health. 2024; 12:1391719.

PMID: 38746005 PMC: 11091249. DOI: 10.3389/fpubh.2024.1391719.

Epidemiological and health economic implications of symptom propagation in respiratory pathogens: A mathematical modelling investigation.

Asplin P, Keeling M, Mancy R, Hill E PLoS Comput Biol. 2024; 20(5):e1012096.

PMID: 38701066 PMC: 11095726. DOI: 10.1371/journal.pcbi.1012096.

References

Asadi S, Bouvier N, Wexler A, Ristenpart W . The coronavirus pandemic and aerosols: Does COVID-19 transmit via expiratory particles?. Aerosol Sci Technol. 2020; 0(0):1-4. PMC: 7157964. DOI: 10.1080/02786826.2020.1749229. View

de Niet A, Waanders B, Walraven I . The role of children in the transmission of mild SARS-CoV-2 infection. Acta Paediatr. 2020; 109(8):1687. PMC: 7262020. DOI: 10.1111/apa.15310. View

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

Miller D, Martin M, Harel N, Tirosh O, Kustin T, Meir M . Full genome viral sequences inform patterns of SARS-CoV-2 spread into and within Israel. Nat Commun. 2020; 11(1):5518. PMC: 7606475. DOI: 10.1038/s41467-020-19248-0. View

McKechnie J, Blish C . The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?. Cell Host Microbe. 2020; 27(6):863-869. PMC: 7237895. DOI: 10.1016/j.chom.2020.05.009. View

Jayaweera M, Perera H, Gunawardana B, Manatunge J . Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ Res. 2020; 188:109819. PMC: 7293495. DOI: 10.1016/j.envres.2020.109819. View

Wander P, Orlov M, Merel S, Enquobahrie D . Risk factors for severe COVID-19 illness in healthcare workers: Too many unknowns. Infect Control Hosp Epidemiol. 2020; 41(11):1369-1370. PMC: 7203168. DOI: 10.1017/ice.2020.178. View

Saini D, Hopkins G, Seay S, Chen C, Perley C, Click E . Ultra-low dose of Mycobacterium tuberculosis aerosol creates partial infection in mice. Tuberculosis (Edinb). 2011; 92(2):160-5. PMC: 3288716. DOI: 10.1016/j.tube.2011.11.007. View

Beldomenico P . Do superspreaders generate new superspreaders? A hypothesis to explain the propagation pattern of COVID-19. Int J Infect Dis. 2020; 96:461-463. PMC: 7211669. DOI: 10.1016/j.ijid.2020.05.025. View

10.

Channappanavar R, Fehr A, Vijay R, Mack M, Zhao J, Meyerholz D . Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016; 19(2):181-93. PMC: 4752723. DOI: 10.1016/j.chom.2016.01.007. View

11.

Fielding J, Kelly H, Mercer G, Glass K . Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age. Influenza Other Respir Viruses. 2013; 8(2):142-50. PMC: 4186461. DOI: 10.1111/irv.12216. View

12.

Watanabe T, Bartrand T, Weir M, Omura T, Haas C . Development of a dose-response model for SARS coronavirus. Risk Anal. 2010; 30(7):1129-38. PMC: 7169223. DOI: 10.1111/j.1539-6924.2010.01427.x. View

13.

Strong R, La Rocca S, Paton D, Bensaude E, Sandvik T, Davis L . Viral Dose and Immunosuppression Modulate the Progression of Acute BVDV-1 Infection in Calves: Evidence of Long Term Persistence after Intra-Nasal Infection. PLoS One. 2015; 10(5):e0124689. PMC: 4425503. DOI: 10.1371/journal.pone.0124689. View

14.

Van Damme W, Dahake R, Delamou A, Ingelbeen B, Wouters E, Vanham G . The COVID-19 pandemic: diverse contexts; different epidemics-how and why?. BMJ Glob Health. 2020; 5(7). PMC: 7392634. DOI: 10.1136/bmjgh-2020-003098. View

15.

Ludvigsson J . Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109(6):1088-1095. PMC: 7228328. DOI: 10.1111/apa.15270. View

16.

Endo A, Abbott S, Kucharski A, Funk S . Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. Wellcome Open Res. 2020; 5:67. PMC: 7338915. DOI: 10.12688/wellcomeopenres.15842.3. View

17.

Wong G, Liu W, Liu Y, Zhou B, Bi Y, Gao G . MERS, SARS, and Ebola: The Role of Super-Spreaders in Infectious Disease. Cell Host Microbe. 2015; 18(4):398-401. PMC: 7128246. DOI: 10.1016/j.chom.2015.09.013. View

18.

Al-Abdely H, Midgley C, Alkhamis A, Abedi G, Lu X, Binder A . Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia. Emerg Infect Dis. 2019; 25(4):753-766. PMC: 6433025. DOI: 10.3201/eid2504.181595. View

19.

Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

20.

Hancioglu B, Swigon D, Clermont G . A dynamical model of human immune response to influenza A virus infection. J Theor Biol. 2007; 246(1):70-86. DOI: 10.1016/j.jtbi.2006.12.015. View